
Billions of dollars are at stake with analyzing and optimizing GTN decisions
Billions of dollars are at stake with analyzing and optimizing GTN decisions
PBM squares the circle by offering a lower drug price—where some payers wouldn’t want it
Current McKesson president, Brian Tyler, will take over in April 2019
Biologics, RxCrossroads units will retain their identity
JC Scott takes over as the PBM business undergoes a transformation
Known as the “King of Cold Chain,” Bishara looks both back and ahead at progress in upgrading pharma’s logistics practices
Will the “United States-Mexico Trade Agreement” replace Nafta?
CVS and Express Scripts open more of the curtain around rebates; formulary exclusions grow
HDA issues a report detailing recalls and returns
Alliance for Regenerative Medicine tries to rationalize how payers address economic value
FDA working group’s effort is part of a larger move to realign drug pricing policies
PBMs, wholesalers and insurers lose over $20 billion in stock value on day of announcement
Will a combination of better diagnosis resources and cost cutting lead to better patient outcomes?
Data are down for 2016-7, but still relatively high compared to prior years; UPDATED
Questions raised over how prescription dosages translate into bulk consumption; IQVIA ‘stand(s) behind our data methodologies’
Eagerly anticipated address avoids major policy changes while chipping away at well-recognized pricing disincentives
With new cellular and genetic therapies, the reimbursement process will need to evolve
Purchases totaled $19.3 billion, up 19% over 2016, say Drug Channels' Adam Fein
Move comes as drug pricing policies get heightened attention in Washington
Company celebrates its growth at annual industry event
While nominal spending was up 1.4%, actual net spending was only 0.6% greater than 2016
Projected growth rates for outsourced work range from 12 to 17%
So-called ‘off the shelf’ CAR-T treatments could change the field just as first products enter commercialization
Existing ‘pay for performance’ models do not scale up well yet